RxDoctor Payments Data

Chun Hong, MD

Internal Medicine · Reston, VANPI 1003844960

Payments from drug & device makers

$8,209in general payments, 2019–2025

Across 371 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Boehringer Ingelheim$648
  • Lilly USA, LLC$634
  • AbbVie$604
  • Amgen$514
  • Johnson & Johnson$504
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$8,182100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,209 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$189,082
Medicare patients
430
Services billed
2,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$95,529
OzempicSemaglutide54$79,256
JardianceEmpagliflozin45$55,616
Tresiba Flextouch U-200Insulin Degludec17$40,908
JanuviaSitagliptin Phosphate20$31,203
XareltoRivaroxaban21$28,320
JanumetSitagliptin Phos/Metformin Hcl20$28,083
LinzessLinaclotide31$22,410
MounjaroTirzepatide22$19,592
Janumet XrSitagliptin Phos/Metformin Hcl11$11,776
MyrbetriqMirabegron11$7,243
Tresiba Flextouch U-100Insulin Degludec16$5,802
SynthroidLevothyroxine Sodium90$5,768
Rosuvastatin Calcium300$5,751
TradjentaLinagliptin12$4,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$495$95,52977 claims
Novo NordiskOzempic$1,420$79,25654 claims
MerckJanuvia, Janumet, Janumet Xr$29$71,06351 claims
Boehringer IngelheimJardiance, Tradjenta$648$60,53157 claims
Johnson & JohnsonXarelto$504$28,32021 claims
AbbVieLinzess, Synthroid$604$28,178121 claims
Lilly USA, LLCMounjaro$634$19,59222 claims
Astellas Pharma US IncMyrbetriq$387$7,24311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Reston

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →